-
Economic evaluation of nivolumab combined with ipilimumab in the first-line t...
The objective of this study was to evaluate the cost-effectiveness of nivolumab in combination with ipilimumab (nivo + ipi) compared to current therapeutic alternatives in... -
Pricing methods in outcome-based contracting: δ2: Willingness-to-pay-based pr...
Aims: Six Delta is a six-dimensional independent platform for outcome-based pricing/contracting. The second dimension (δ2) estimates prices on the basis of four... -
Burden of disease and costs associated with type 2 diabetes in emerging and e...
To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). Three systematic literature reviews were conducted in... -
The economic burden of common adverse events associated with metastatic color...
Aims: Adverse events (AEs) associated with treatments for metastatic colorectal cancer (mCRC) may compromise the course of treatment, impact quality-of-life, and increase... -
Cost-effectiveness analysis of apixaban compared to other direct oral anticoa...
Several direct oral anticoagulants (DOACs) have been approved by the European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis was to analyze... -
dedup_wf_001--70e01640ccad9d8bc91e69552a448a25
Aims: In this study we examined the extent to which Marketplace health insurance subscribers reenroll a second year. Among reenrollees, we sought to examine movement to more and... -
dedup_wf_001--7461e22ba55f012f42ded7c8480fb3eb
OBJECTIVES: Genomic profiling in oncology is vital for determining eligible patients for mutation-specific targeted therapies. Use of commercial genomic testing has the... -
Disease burden on health care by pain severity and usual analgesic treatment ...
Osteoarthritis (OA) pain is a health care highly demanding and costing condition. To estimate disease burden on health care in OA in Spain, determining whether burden differs by... -
Cost-effectiveness and budget impact analysis of infliximab and its biosimila...
This study aimed to conduct a cost-effectiveness analysis of infliximab and its biosimilar compared to conventional therapy in refractory moderate-to-severe Crohn’s disease (CD)... -
Economic burden of subsequent fracture in osteoporosis patients in South Korea
This study aimed to assess the economic burden of subsequent fracture in osteoporosis patients with incident fracture. The authors conducted a retrospective cohort analysis of... -
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the trea...
Background: Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have limited treatment options and poor prognoses. Tisagenlecleucel, a chimeric... -
Vaso-occlusive crises and costs of sickle cell disease in patients with comme...
Aim: To characterize vaso-occlusive crises (VOCs) and describe healthcare costs among commercially-insured, Medicaid-insured, and Medicare-insured patients with sickle cell... -
Clinical and economic burden of postsurgical complications of high-risk surge...
Background: This study aimed to understand the clinical and economic burden associated with postsurgical complications in high-risk surgeries in Thailand. Methods: A cost and... -
A comparison of measurement properties between UK SF-6D and English EQ-5D-5L ...
Evidence is limited for comparative psychometric properties between EQ-5D-5L and SF-6D. Therefore, this study compared psychometric properties between those instruments using... -
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with...
Aims: An increase in the prevalence of antimicrobial resistance among gram-negative pathogens has been noted recently.[1] A challenge in empiric treatment of complicated... -
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabet...
Background and Aims: The ReFLeCT study demonstrated that switching to insulin degludec from other basal insulins was associated with reductions in glycated hemoglobin and... -
Budget impact analysis of betrixaban for venous thromboembolism prophylaxis i...
Objectives: Venous thromboembolism (VTE) incurs substantial costs to the UK National Health Service (NHS). Betrixaban is approved in the US for VTE prophylaxis with a...
